1. Feasibility of a Randomized, Interventional Pilot Clinical Study of Oral Cannabinoids in People with HIV on Antiretroviral Therapy: CTNPT 028.
- Author
-
Mboumba Bouassa, Ralph-Sydney, Needham, Judy, Nohynek, Dana, Samarani, Suzanne, Bobeuf, Florian, Del Balso, Lina, Paisible, Natalie, Vertzagias, Claude, Sebastiani, Giada, Margolese, Shari, Mandarino, Enrico, Singer, Joel, Klein, Marina, Lebouché, Bertrand, Cox, Joseph, Vulesevic, Branka, Müller, Alison, Lau, Elisa, Routy, Jean-Pierre, and Jenabian, Mohammad-Ali
- Subjects
ANTIRETROVIRAL agents ,HIV-positive persons ,CANNABINOIDS ,CANNABIDIOL ,SAMPLE size (Statistics) - Abstract
Cannabis-based medicines (CBMs) could help reduce systemic inflammation in people with HIV (PWH). In a prospective, randomized pilot study we enrolled participants from August 2021–April 2022 with HIV, aged ≥18 and on antiretroviral therapy and randomly assigned them to cannabidiol (CBD) ± Δ9-tetrahydrocannabinol (THC) capsules for 12 weeks with the primary objective being to assess safety and tolerability. Here we report on timeliness to study initiation, enrolment, compliance and retention rates. The target sample size was not reached. Two hundred and five individuals were approached, and 10 consented and were randomized; the rest refused (reasons: cannabis-related stigma/discomfort; too many study visits/insufficient time; unwillingness to undergo a "washout period" for three weeks) or were not eligible. The age of those randomized was 58 years (IQR 55–62); 80% were male. Only three met all criteria (30% enrolment compliance); seven were enrolled with minor protocol deviations. Compliance was excellent (100%). Eight (80%) participants completed the study; two (20%) were withdrawn for safety reasons (transaminitis and aggravation of pre-existing anemia). Time to study initiation and recruitment were the most challenging aspects. Ongoing work is required to reduce stigma related to CBMs. Future studies should find a balance between the requirements for safety monitoring and frequency of study visits. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF